Cambrex

Activities: Ingredients

Trending Articles

  1. Pharma in 2025–2026: AI, China and the new era of drug development In 2025, the pace of change throughout chemical and pharmaceutical manufacturing is accelerating, creating a complex mix of emerging opportunities and structural challenges...
  2. When science meets security: the future of small molecule outsourcing Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence...
  3. Novo Nordisk wins positive ruling for semaglutide compound patent from China’s Supreme People’s Court The company has welcomed a decision by China’s Supreme People’s Court affirming the validity of its semaglutide compound patent, strengthening confidence for foreign...
  4. Beyond the portal: building the digital foundations for global CGT delivery As 2025 unfolds and planning for 2026 gathers momentum, manufacturers face a landscape in which supply chain uncertainty, sustainability demands and digital transformation are...
  5. Ultra-high potency and its impact on pharmaceutical outsourcing This article explores the emerging distinction between high and ultra-high potency APIs, highlighting the implications for pharmaceutical outsourcing and risk management in an...

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

Related Content

Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Manufacturing

Cambrex optimises the peptide synthesis process with novel LPPS technology

The manufacturing solution reduces the reliance on specialised, solid-phase reactors, while being easily scalable and less resource-intensive
Distribution

Cambrex expands stability storage capabilities with novel US facility

The facility allows for pharmaceutical and medical device storage at a wide range of temperatures and humidity levels, serving the US market with next day delivery
Manufacturing

Cambrex completes expansion at small molecule API facility

The company has announced it has doubled the size of its small molecule active pharmaceutical ingredient (API) manufacturing facility
Manufacturing

Cambrex completes Snapdragon Chemistry acquisition

The company continues to expand its portfolio of specialised solutions for pharmaceutical development and manufacturing
Manufacturing

Cambrex set to acquire Snapdragon Chemistry

“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing"
Manufacturing

Cambrex invests in 21,000 sqft R&D facility in Minnesota

The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances
Subscribe now